Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue
+14.0%
EPS
−277.9%
Free cash flow
−233.0%
Total debt
−10.5%

Quarter to September 2026, against a year earlier

118.77 0.76 +0.64%
Market cap
$24.1B
P/E
56.3×
Fwd P/E
55.6×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a

Incyte Corporation (INCY) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Incyte Corporation (INCY) trades at a EV/FCF of 29.7×. Over the past ten years it has ranged from −14,386× (April 2018) to 853× (November 2024); the current reading is higher than 63% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 11.8× (77.16%)
FY2024 51.8× 111.21%
FY2023 24.5× 51.40%
FY2022 16.2× (33.57%)
FY2021 24.4× —
FY2020 −55.2× —
FY2019 26.4× (42.64%)
FY2018 46.0× —
FY2017 −95.6× —
FY2016 103× (66.20%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 30.7× 218.19%
Jun 2026 9.6× (7.40%)
Mar 2026 10.4× (12.09%)
Dec 2025 11.8× 1.23%
43 more quarters

Against its own ten years

Low −14,386× High 853×
Ten-year median 22.2×
Current reading's percentile 57

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on INCY